S, Jaya Kumari (2018) COUMARIN (ESCULETIN) - AN ANTIRHEUMATOID ARTHRITIC COMPOUND: AN UPDATE. Asian Journal of Pharmaceutical and Clinical Research, 11. ISSN 0974-2441
![[thumbnail of _editorajpcr,+31710-Article+Text-147148-1-10-20190103.pdf]](https://ir.vistas.ac.in/style/images/fileicons/archive.png) Archive
            
              
Archive
_editorajpcr,+31710-Article+Text-147148-1-10-20190103.pdf
Download (1MB)
Abstract
COUMARIN (ESCULETIN) - AN ANTIRHEUMATOID ARTHRITIC COMPOUND: AN UPDATE Jaya Kumari S
Context: Esculetin is a natural polyphenolic compound. It is chemically 6,7-dihydroxycoumarin and one of the ingredients of Cortex fraxini, a Chinese traditional medicine. It is used as a dietary supplement and found as non-toxic. Recently, there are many research works evaluated on esculetin in arthritis with supported molecular mechanisms.Objectives: Esculetin becoming more attractive prodrug for arthritis. Hence, the present minireview will consolidate the targeted site of esculetin in the treatment of arthritis over the past decade.Results: The most important molecular mechanism of esculetin is an antioxidant activities with decreased level of reactive oxygen species/reactive nitrogen species. It also inhibited lipoxygenase 5, lipoxygenase 12, and tyrosinase enzymes. It reduces the inflammation by modulating the key inflammatory enzyme matrix metalloproteinase-1 activity. It also lowers the nitrous oxide and prostaglandin E2 level in synovial fluid. Esculetin derivatives such as 5-methoxy esculetin inhibited the activity of nitrogen-activated protein kinases. The updated data also reveal that esculetin suppresses the leukotriene B4 level in plasma of adjuvant-induced arthritis tested animals.Conclusion: The presented update showed that esculetin may be useful as a tool in regulating the mechanism and physiological functions of the inflammatory mediators and enzyme. Hence, the presented review work may be considered as a scientific proof for the development of an attractive drug candidate for the patient with rheumatoid arthritis.
   12 28 2018   10.22159/ajpcr.2018.v11s4.31710 https://innovareacademics.in/journals/index.php/ajpcr/article/view/31710   https://innovareacademics.in/journals/index.php/ajpcr/article/viewFile/31710/16629     https://innovareacademics.in/journals/index.php/ajpcr/article/viewFile/31710/16629
| Item Type: | Article | 
|---|---|
| Subjects: | Pharmacognosy > Pharmacognosy | 
| Domains: | Pharmacognosy | 
| Depositing User: | Mr IR Admin | 
| Date Deposited: | 02 Oct 2024 06:53 | 
| Last Modified: | 02 Oct 2024 06:53 | 
| URI: | https://ir.vistas.ac.in/id/eprint/7888 | 



 Dimensions
 Dimensions Dimensions
 Dimensions